377 related articles for article (PubMed ID: 26201312)
1. Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis.
Ashida K; Sakurai Y; Nishimura A; Kudou K; Hiramatsu N; Umegaki E; Iwakiri K; Chiba T
Aliment Pharmacol Ther; 2015 Sep; 42(6):685-95. PubMed ID: 26201312
[TBL] [Abstract][Full Text] [Related]
2. Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis.
Ashida K; Sakurai Y; Hori T; Kudou K; Nishimura A; Hiramatsu N; Umegaki E; Iwakiri K
Aliment Pharmacol Ther; 2016 Jan; 43(2):240-51. PubMed ID: 26559637
[TBL] [Abstract][Full Text] [Related]
3. Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis.
Xiao Y; Zhang S; Dai N; Fei G; Goh KL; Chun HJ; Sheu BS; Chong CF; Funao N; Zhou W; Chen M
Gut; 2020 Feb; 69(2):224-230. PubMed ID: 31409606
[TBL] [Abstract][Full Text] [Related]
4. Maintenance for healed erosive esophagitis: Phase III comparison of vonoprazan with lansoprazole.
Ashida K; Iwakiri K; Hiramatsu N; Sakurai Y; Hori T; Kudou K; Nishimura A; Umegaki E
World J Gastroenterol; 2018 Apr; 24(14):1550-1561. PubMed ID: 29662293
[TBL] [Abstract][Full Text] [Related]
5. Randomised clinical trial: efficacy and safety of vonoprazan vs. lansoprazole in patients with gastric or duodenal ulcers - results from two phase 3, non-inferiority randomised controlled trials.
Miwa H; Uedo N; Watari J; Mori Y; Sakurai Y; Takanami Y; Nishimura A; Tatsumi T; Sakaki N
Aliment Pharmacol Ther; 2017 Jan; 45(2):240-252. PubMed ID: 27891632
[TBL] [Abstract][Full Text] [Related]
6. Randomised clinical trial: vonoprazan versus lansoprazole for the initial relief of heartburn in patients with erosive oesophagitis.
Oshima T; Arai E; Taki M; Kondo T; Tomita T; Fukui H; Watari J; Miwa H
Aliment Pharmacol Ther; 2019 Jan; 49(2):140-146. PubMed ID: 30589965
[TBL] [Abstract][Full Text] [Related]
7. Vonoprazan versus Lansoprazole for the Initial Treatment of Reflux Esophagitis: A Cost-effectiveness Analysis in Japan.
Habu Y
Intern Med; 2019 Sep; 58(17):2427-2433. PubMed ID: 31178490
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Vonoprazan for Proton Pump Inhibitor-Resistant Reflux Esophagitis.
Hoshino S; Kawami N; Takenouchi N; Umezawa M; Hanada Y; Hoshikawa Y; Kawagoe T; Sano H; Hoshihara Y; Nomura T; Iwakiri K
Digestion; 2017; 95(2):156-161. PubMed ID: 28190016
[TBL] [Abstract][Full Text] [Related]
9. Vonoprazan-Based Regimen Is More Useful than PPI-Based One as a First-Line
Maruyama M; Tanaka N; Kubota D; Miyajima M; Kimura T; Tokutake K; Imai R; Fujisawa T; Mori H; Matsuda Y; Wada S; Horiuchi A; Kiyosawa K
Can J Gastroenterol Hepatol; 2017; 2017():4385161. PubMed ID: 28349044
[No Abstract] [Full Text] [Related]
10. Efficacy of Vonoprazan, a Novel Potassium-Competitive Acid Blocker, in Patients with Proton Pump Inhibitor-Refractory Acid Reflux.
Akiyama J; Hosaka H; Kuribayashi S; Moriyasu S; Hisada Y; Okubo H; Watanabe K; Imbe K; Nagata N; Kojima Y; Yokoi C; Uemura N; Shimoyama Y; Kawamura O; Yamada M; Kusano M
Digestion; 2020; 101(2):174-183. PubMed ID: 30897577
[TBL] [Abstract][Full Text] [Related]
11. Vonoprazan 10 mg or 20 mg vs. lansoprazole 15 mg as maintenance therapy in Asian patients with healed erosive esophagitis: A randomized controlled trial.
Xiao Y; Qian J; Zhang S; Dai N; Chun HJ; Chiu C; Chong CF; Funao N; Sakurai Y; Eisner JD; Xie L; Chen M
Chin Med J (Engl); 2024 Apr; 137(8):962-971. PubMed ID: 38654422
[TBL] [Abstract][Full Text] [Related]
12. Vonoprazan Versus Lansoprazole for Healing and Maintenance of Healing of Erosive Esophagitis: A Randomized Trial.
Laine L; DeVault K; Katz P; Mitev S; Lowe J; Hunt B; Spechler S
Gastroenterology; 2023 Jan; 164(1):61-71. PubMed ID: 36228734
[TBL] [Abstract][Full Text] [Related]
13. Effect of Vonoprazan, a Potassium-Competitive Acid Blocker, on the
Takimoto M; Tomita T; Yamasaki T; Fukui S; Taki M; Okugawa T; Kondo T; Kono T; Tozawa K; Arai E; Ohda Y; Oshima T; Fukui H; Watari J; Miwa H
Dig Dis Sci; 2017 Mar; 62(3):739-745. PubMed ID: 28083842
[TBL] [Abstract][Full Text] [Related]
14. The efficacy and safety of keverprazan, a novel potassium-competitive acid blocker, in treating erosive oesophagitis: a phase III, randomised, double-blind multicentre study.
Chen S; Liu D; Chen H; Liao A; Li F; Liu C; Li X; Li S; Zhang Y; Wang Y; Xia M; Guo Q; Miao X; Wen Z; Xu M; Yin H; Chen H; Chen M; Xiao Y
Aliment Pharmacol Ther; 2022 Jun; 55(12):1524-1533. PubMed ID: 35505467
[TBL] [Abstract][Full Text] [Related]
15. Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study.
Kawai T; Oda K; Funao N; Nishimura A; Matsumoto Y; Mizokami Y; Ashida K; Sugano K
Gut; 2018 Jun; 67(6):1033-1041. PubMed ID: 29196436
[TBL] [Abstract][Full Text] [Related]
16. Clinical trials: healing of erosive oesophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed-release formulation--results from two randomized controlled studies.
Sharma P; Shaheen NJ; Perez MC; Pilmer BL; Lee M; Atkinson SN; Peura D
Aliment Pharmacol Ther; 2009 Apr; 29(7):731-41. PubMed ID: 19183157
[TBL] [Abstract][Full Text] [Related]
17. Randomised clinical trial: 3-year interim analysis results of the VISION trial to evaluate the long-term safety of vonoprazan as maintenance treatment in patients with erosive oesophagitis.
Haruma K; Kinoshita Y; Yao T; Kushima R; Akiyama J; Aoyama N; Kanoo T; Miyata K; Kusumoto N; Uemura N
BMC Gastroenterol; 2023 May; 23(1):139. PubMed ID: 37127558
[TBL] [Abstract][Full Text] [Related]
18. [Vonoprazan: a novel potassium-competitive acid blocker].
Sugano K
Nihon Rinsho; 2015 Jul; 73(7):1163-8. PubMed ID: 26165074
[TBL] [Abstract][Full Text] [Related]
19. Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study.
Mizokami Y; Oda K; Funao N; Nishimura A; Soen S; Kawai T; Ashida K; Sugano K
Gut; 2018 Jun; 67(6):1042-1051. PubMed ID: 28988197
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of vonoprazan in prevention of bleeding from endoscopic submucosal dissection-induced gastric ulcers: a prospective randomized phase II study.
Hamada K; Uedo N; Tonai Y; Arao M; Suzuki S; Iwatsubo T; Kato M; Shichijo S; Yamasaki Y; Matsuura N; Nakahira H; Kanesaka T; Yamamoto S; Akasaka T; Hanaoka N; Takeuchi Y; Higashino K; Ishihara R; Okada H; Iishi H; Fukui K; Shimokawa T
J Gastroenterol; 2019 Feb; 54(2):122-130. PubMed ID: 29943163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]